ImmunoPharma AS (ImmunoPharma), the parent company of Nordic Healthy Living AS (Nordic Healthy Living AS), has requested the board of Eqology AS (Eqology) to call for a general meeting to resolve a de-listing of Eqology's shares from NOTC during December 2020. The liquidity of the shares of Eqology on NOTC has been very limited, with a turnover on NOTC of just 611,727 shares (0,56%) out of 109,683,874 outstanding shares, at an average price of NOK 0.65 over the last 12 months. Under Eqology's listing agreement with NOTC, the requirement for de-listing of Eqology's shares is that more than 2/3 of the outstanding shares vote in favour of such proposal. Nordic Healthy Living currently holds appr. 74.1% of the outstanding shares in Eqology and ImmunoPharma will procure that its wholly owned subsidiary votes in favour of said proposal on the upcoming extraordinary general meeting.

ImmunoPharma has in 2020 bought a total of 22 420 456 shares in Eqology at a price of NOK 1.0 per share from key shareholders and members of management in Eqology AS in exchange for subscription of shares in ImmunoPharma at NOK 4.5 per share. Reference is particularly made to the notice published on 6 October 2020 regarding ImmunoPharma's purchase of 13,169,429 shares from BG Consult AS (controlled by former CEO Børre Gjersvik) and 4,500,000 shares from Momentum Consult & Invest AS (controlled by Business Partner Robert Heldal).

In connection with the de-listing, ImmunoPharma will offer shareholders that hold more than 5,000 shares in Eqology to sell their shares in Eqology for NOK 1.0 on the condition that the purchase price is used to subscribe for new shares in ImmunoPharma at price of NOK 4.5 per share. Shareholders that hold less than 5,000 shares in Eqology will be offered to sell their shares in Eqology for NOK 1.0 against settlement in cash.

For questions regarding the offer from ImmunoPharma, contact:

Frank Bjordal
Tel: 99 51 73 72
E-mail: frank@universal-exports.no

Kim Øien
Tel: 95 21 69 72
E-mail: kim@tgmontgomery.no